Multiple myeloma laboratory tests: Difference between revisions
Jump to navigation
Jump to search
Shyam Patel (talk | contribs) No edit summary |
m (Bot: Removing from Primary care) |
||
| (14 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Multiple myeloma}} | {{Multiple myeloma}} | ||
{{CMG}} {{AE}}{{HL}} {{shyam}} | {{CMG}} {{AE}} {{HMHJ}}; {{HL}}; {{shyam}} | ||
==Overview== | ==Overview== | ||
Laboratory findings consistent with the diagnosis of multiple myeloma include abnormal [[complete blood count]], [[ | Laboratory findings consistent with the [[diagnosis]] of [[multiple myeloma]] include abnormal [[complete blood count]], abnormal [[basic metabolic panel]], elevated monoclonal [[protein]] on serum [[electrophoresis]], elevated [[serum]] free [[Light chain|light chains]], and presence of [[Multiple myeloma|myeloma]]-specific [[protein]] markers by [[immunohistochemistry]] or [[immunophenotyping]]. Some of the laboratory tests are factors that determine the stage of [[Multiple myeloma|multiple myeloma.]] | ||
==Laboratory Findings== | ==Laboratory Tests== | ||
=== Initial Tests === | |||
* [[Complete blood counts|Complete blood count]] with differential | |||
* [[Serum albumin]] | |||
* [[Calcium|Serum calcium]] | |||
* [[Serum]] [[Electrolyte|electrolytes]] | |||
* [[Serum creatinine]] | |||
* [[Serum]] [[urea]] | |||
* [[Serum]] [[nitrogen]] | |||
=== Confirmatory Tests === | |||
* 24-hour [[urine]] [[protein]] | |||
* [[Beta-2 microglobulin|β<sub>2</sub>-microglobulin]] | |||
* [[Lactate dehydrogenase]] | |||
* [[Serum]] free [[light chain]] assay | |||
* Serum [[immunofixation]] [[electrophoresis]] | |||
* [[Serum protein electrophoresis]] | |||
* [[Serum]] quantitative [[immunoglobulins]] | |||
* [[Skeletal survey]] | |||
* [[Urine]] [[immunofixation]] [[electrophoresis]] | |||
* [[Urine]] [[protein electrophoresis]] | |||
=== Tests Performed by Oncologist === | |||
* [[Bone marrow aspiration]] | |||
* [[Bone marrow biopsy]] | |||
* [[Cytogenetics]] studies | |||
* [[Flow cytometry]] | |||
* [[Fluorescence in situ hybridization]] | |||
* [[Immunohistochemistry]] | |||
=== Tests in Special Circumstances === | |||
* [[Bone]] [[densitometry]] | |||
* [[PET scan|PET/CT]] or whole-body [[MRI]] | |||
* [[Serum]] [[viscosity]] | |||
* [[Tissue]] [[biopsy]] of [[Bone|bony]] or other [[lesion]] | |||
== Laboratory Findings == | |||
===Complete blood count=== | |||
*[[Anemia]]<ref name="canada">Multiple myeloma. Canadian Cancer Society(2015) http://www.cancer.ca/en/cancer-information/cancer-type/multiple-myeloma/diagnosis/?region=mb#blood_chem Accessed on September, 20th 2015</ref><ref name="wiki">Multiple myeloma. Wikipedia(2015)https://en.wikipedia.org/wiki/Multiple_myeloma#Pathophysiology Accessed on September 2015</ref> | |||
*[[Thrombocytopenia]] | *[[Thrombocytopenia]] | ||
*[[Leukopenia]] | *[[Leukopenia]] | ||
===Peripheral blood smear=== | |||
*[[Rouleaux formation]] of red blood cells | *[[Rouleaux formation]] of red blood cells: This is defined as the stacking of 4 or more [[red blood cells]]. In healthy individuals, the zeta potential of [[red blood cells]] causes intercellular repulsion. However, in patients with multiple myeloma, there are many positively charged paraproteins, which antagonizes the negative charge on [[red blood cells]] and allows for stacking.<ref name="canada" /><ref name="wiki" /> | ||
===Basic metabolic panel=== | |||
*[[Hypercalcemia]] due to increased [[osteoclasts]] activity: This is one of the defining features of end-organ damage in multiple myeloma. | *[[Hypercalcemia]] due to increased [[osteoclasts]] activity: This is one of the defining features of end-organ damage in multiple myeloma. | ||
*Increased [[serum creatinine]] level due to reduced [[renal function]]: This is one of the defining features of end-organ damage in multiple myeloma. | *Increased [[serum creatinine]] level due to reduced [[renal function]]: This is one of the defining features of end-organ damage in multiple myeloma. | ||
| Line 24: | Line 59: | ||
*High lactate dehydrogenase: This occurs in stage III multiple myeloma as defined by the Revised-International Staging System (R-ISS). | *High lactate dehydrogenase: This occurs in stage III multiple myeloma as defined by the Revised-International Staging System (R-ISS). | ||
===Serum protein electrophoresis=== | |||
*[[Protein electrophoresis]] is a method that separates proteins in the serum or urine | *[[Protein electrophoresis]] is a method that separates proteins in the serum or urine. | ||
*70% of cases have high levels of [[IgG]] | *70% of cases have high levels of [[IgG]] | ||
*20% of cases have high levels of [[IgA]] | *20% of cases have high levels of [[IgA]] | ||
| Line 31: | Line 66: | ||
*Rarely κ- or λ-light chains may be secreted in isolation | *Rarely κ- or λ-light chains may be secreted in isolation | ||
===Urine studies=== | |||
*Presence of monoclonal paraprotein on urine protein electrophoresis | *Presence of monoclonal paraprotein on urine protein electrophoresis | ||
*Elevated 24-hour urine protein | *Elevated 24-hour urine protein | ||
*Elevated urine free light chains | *Elevated urine free light chains | ||
===Free light chain immunoassay=== | |||
*Elevated free kappa light chain | *Elevated free kappa light chain | ||
*Elevated free lambda light chain | *Elevated free lambda light chain | ||
*Elevated free light chain ratio | *Elevated free light chain ratio | ||
*Potentially offers an improvement in monitoring disease progression and response to treatment | *Potentially offers an improvement in monitoring disease progression and response to treatment | ||
===Immunofixation=== | |||
*Identifies the type of M-protein or immunoglobulin light chain detected by serum or urine electrophoresis | *Identifies the type of M-protein or immunoglobulin light chain detected by serum or urine electrophoresis | ||
===Quantitative immunoglobulin assay=== | |||
*Quantitative measurement of IgA, IgG, IgM immunoglobulins to detect immune paresis | *Quantitative measurement of IgA, IgG, IgM immunoglobulins to detect immune paresis | ||
*Monoclonal gammopathy (IgA and/or IgG peak) | *Monoclonal gammopathy (IgA and/or IgG peak) | ||
| Line 51: | Line 86: | ||
*Elevated β2-microglobulin level: β2-microglobulin level is one factor that determines the stage of multiple myeloma. | *Elevated β2-microglobulin level: β2-microglobulin level is one factor that determines the stage of multiple myeloma. | ||
===Immunophenotyping=== | |||
*Multiple myeloma cells are typically [[CD56]], [[CD38]], [[CD138]] positive and [[CD19]] and [[CD45]] negative. | *Multiple myeloma cells are typically [[CD56]], [[CD38]], [[CD138]] positive and [[CD19]] and [[CD45]] negative. | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Medicine]] | |||
[[Category: | |||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category:Neurology]] | [[Category:Neurology]] | ||
[[Category:Neurosurgery]] | [[Category:Neurosurgery]] | ||
[[Category:Oncology]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Surgery]] | |||
Latest revision as of 22:47, 29 July 2020
|
Multiple myeloma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Multiple myeloma laboratory tests On the Web |
|
American Roentgen Ray Society Images of Multiple myeloma laboratory tests |
|
Risk calculators and risk factors for Multiple myeloma laboratory tests |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Hannan Javed, M.D.[2]; Haytham Allaham, M.D. [3]; Shyam Patel [4]
Overview
Laboratory findings consistent with the diagnosis of multiple myeloma include abnormal complete blood count, abnormal basic metabolic panel, elevated monoclonal protein on serum electrophoresis, elevated serum free light chains, and presence of myeloma-specific protein markers by immunohistochemistry or immunophenotyping. Some of the laboratory tests are factors that determine the stage of multiple myeloma.
Laboratory Tests
Initial Tests
- Complete blood count with differential
- Serum albumin
- Serum calcium
- Serum electrolytes
- Serum creatinine
- Serum urea
- Serum nitrogen
Confirmatory Tests
- 24-hour urine protein
- β2-microglobulin
- Lactate dehydrogenase
- Serum free light chain assay
- Serum immunofixation electrophoresis
- Serum protein electrophoresis
- Serum quantitative immunoglobulins
- Skeletal survey
- Urine immunofixation electrophoresis
- Urine protein electrophoresis
Tests Performed by Oncologist
- Bone marrow aspiration
- Bone marrow biopsy
- Cytogenetics studies
- Flow cytometry
- Fluorescence in situ hybridization
- Immunohistochemistry
Tests in Special Circumstances
Laboratory Findings
Complete blood count
Peripheral blood smear
- Rouleaux formation of red blood cells: This is defined as the stacking of 4 or more red blood cells. In healthy individuals, the zeta potential of red blood cells causes intercellular repulsion. However, in patients with multiple myeloma, there are many positively charged paraproteins, which antagonizes the negative charge on red blood cells and allows for stacking.[1][2]
Basic metabolic panel
- Hypercalcemia due to increased osteoclasts activity: This is one of the defining features of end-organ damage in multiple myeloma.
- Increased serum creatinine level due to reduced renal function: This is one of the defining features of end-organ damage in multiple myeloma.
- Abnormal blood urea nitrogen
- High alkaline phosphatase level
- High serum protein level with normal/decreased albumin level: This creates a high protein gap, which is defined as the difference between the albumin level and the total protein level.
- High lactate dehydrogenase: This occurs in stage III multiple myeloma as defined by the Revised-International Staging System (R-ISS).
Serum protein electrophoresis
- Protein electrophoresis is a method that separates proteins in the serum or urine.
- 70% of cases have high levels of IgG
- 20% of cases have high levels of IgA
- 5–10% of cases have only immunoglobulin light chains (Bence Jones proteins)
- Rarely κ- or λ-light chains may be secreted in isolation
Urine studies
- Presence of monoclonal paraprotein on urine protein electrophoresis
- Elevated 24-hour urine protein
- Elevated urine free light chains
Free light chain immunoassay
- Elevated free kappa light chain
- Elevated free lambda light chain
- Elevated free light chain ratio
- Potentially offers an improvement in monitoring disease progression and response to treatment
Immunofixation
- Identifies the type of M-protein or immunoglobulin light chain detected by serum or urine electrophoresis
Quantitative immunoglobulin assay
- Quantitative measurement of IgA, IgG, IgM immunoglobulins to detect immune paresis
- Monoclonal gammopathy (IgA and/or IgG peak)
- Reverse albumin:globulin ratio (low albumin, high globulin)
- Elevated β2-microglobulin level: β2-microglobulin level is one factor that determines the stage of multiple myeloma.
Immunophenotyping
References
- ↑ 1.0 1.1 Multiple myeloma. Canadian Cancer Society(2015) http://www.cancer.ca/en/cancer-information/cancer-type/multiple-myeloma/diagnosis/?region=mb#blood_chem Accessed on September, 20th 2015
- ↑ 2.0 2.1 Multiple myeloma. Wikipedia(2015)https://en.wikipedia.org/wiki/Multiple_myeloma#Pathophysiology Accessed on September 2015